Global Genome Engineering Market By Overview
Introduction:
Genome editing also known as gene editing is a group of technologies that give scientists the ability to change the DNA of an organism genome editing is a method of making specific changes to the DNA of a cell. It can be used to add, remove or change DNA in the genome, human genome engineering technology can be used on somatic cells (non-heritable), germ line cells (not for reproduction) and germ line cells (for reproduction). This technology makes it possible to add, remove, or replace genetic material at specific locations in the genome. Genomic engineering is the synthetic assembly of entire chromosomal DNA derived more or less from natural genomic sequences. It is the modification of an organism's genetic code, modifications include deleting nucleotides to knock out a gene, adding nucleotides to knock in a protein, or editing nucleotides to create a mutation. Chromosomal DNA is assembled through genomic engineering by inserting, deleting, replacing, or replacing DNA bases in an organism. CRISPR is a technology used to edit genes along with other versions of CRISPR, allowing scientists to manipulate genes in more precise ways such as adding new segments of DNA or editing single DNA letters. Scientists is used CRISPR to detect specific targets, such as RNA from cancer cells, A digital genome is a digital set of genetic material that resides in an organism, it is considered a convenient way to collect data on chronic diseases and is widely practiced by specialists to get a closer look at genetic complications. Increasing use of genetic engineering technology in pharmaceutical research and development activities is a major factor driving the market growth.
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
Global Genome Engineering Market By Dynamics
Increasing demand of synthetic genes & high cost of genome
Increasing funding and investment in research and development of new genetic engineering technologies, increasing demand for synthetic genes is expected to drive market growth, and the need to act against common cancers and infectious diseases is another primary driver for Global growth. Market However, lack of R&D centers around the world which they require drags down the growth of the Global market during the forecast period. The high cost of genome engineering technology is expected to be a major factor, restraining the growth of the genome engineering market during the forecast period, and ethical issues regarding the use of gene editing are likely to hamper the market growth.
Technological advancement
Manufacturers in the genome engineering market are developing advanced versions of their products due to new age technological advancements. Increasing research and development to discover new technologies including genome engineering is expected to drive the genome engineering market and also, several genome technologies are in trials for the treatment of such diseases and are expected to be approved in the near future. Increasing technological progress is driven by the rapidly evolving CRISPR technology with its wide range of applications for gene editing. This technology is primarily used to gain access to genetically modified crops by delivering gene-editing reagents to plants. In October 2022, New R&D norms to fast-track research on genome-edited crops. Scientists say genome-edited plants differ from genetically-modified organism (GMO) technology. Genome editing is a group of technologies that give scientists the ability to alter an organism's DNA
Global Genome Engineering Market By Segmentation
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
Genome Engineering Market is segmented based on technology, application, end user and region.
Genome Engineering Market, By Technology
On the basis of technology, the Genome Engineering Market is segmented into CRISPR, TALEN, ZFN, and Others. Genome engineering technologies such as CRISPR, which are used to target, cut and edit nucleotides (aka gene editing) and can alter gene functions by altering epigenetic marks and three-dimensional chromatin structure. TALEN, which consists of a pair of DNA binding proteins linked to FokI nuclease, and CRISPR, which is a complex between Cas9 nuclease and a target-specific single guide RNA (sgRNA). ZFNs and TALENs enable a wide range of genetic modifications by inducing DNA double-strand breaks that stimulate error-prone non-homologous end joining or homology-directed repair at specific genomic locations.
Genome Engineering Market, By Application
On the basis of application, the target market is classified into Cell line Engineering and Genetic Engineering. Genetic engineering plays an important role in drug development. Microbial and plant-based materials are being used to produce large quantities of useful drugs, vaccines, enzymes and hormones at low cost. A cell line is a general term that applies to a defined population of cells that can be maintained in culture for long periods of time, maintaining the stability of specific phenotypes and functions.
Genome Engineering Market, By End User
On the basis of end user, the Genome Engineering Market is segmented into Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Contract Research Organizations. The pharmaceutical segment is expected to hold the largest market share during the forecast period. The increasing prevalence of infectious diseases and cancer is driving research activities worldwide. Investment by pharmaceutical companies to develop new treatments is expected to drive market growth over the forecast period. Increasing R&D activities and new trends in treating genetic diseases are also fueling the market growth for the pharmaceutical industry.
Regional Insights:
On region the Genome Engineering Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa The genome engineering market in North America accounted for highest revenue share as compared to other region. This can be attributed to increasing adoption of advanced techniques in the countries of the region. Also, the market in Europe is expected to account for second-highest revenue share in the global market, followed by the market in Asia Pacific.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2022 |
|
Forecast period |
2022– 2032 |
|
Market representation |
Revenue in USD Billion & CAGR from 2022 to 2032 |
|
Market Segmentation |
By Technology - CRISPR, TALEN, ZFN, and Others By Application - Cell line Engineering and Genetic Engineering By End-User - Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Contract Research Organizations |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Recent Development:
- In September 2022, The Vatican is gathering experts to look into the ethics of genome editing in September The Pontifical Academy for Life held its first international conference on the topic of “Ethics of Engineering Life” in Rome, the Vatican institute announced in a statement released on September 20.
- In October 2022, Fundamentals of Genetic Engineering. The term genetic engineering refers to the technology of altering genes. Unlike selective breeding, which only selects for traits already found in nature, genetic engineering works directly on the genetic material to change an organism's traits. Genetic engineering is the cornerstone of modern biotechnology and has the power to alter the molecular basis of all forms of life in humans.
- In June 2021, Allel Biotechnology and Alpine Biotherapeutics Corporation announced an agreement to develop induced pluripotent stem cells to treat retinal diseases. This strategy helped the company develop an advanced product portfolio.
Segments Covered in the Report:
This report forecasts revenue growth at Global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Genome Engineering Market report based on technology, application, end user and region:
Genome Engineering Market, By Technology:
- CRISPR
- TALEN
- ZFN
- Others
Genome Engineering Market, By Application:
- Cell line Engineering
- Genetic Engineering
Genome Engineering Market, By End User:
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research Organizations
Genome Engineering Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
- Middle East & Africa
Global Genome Engineering Market By Key Players
The key players operating the Genome Engineering Market includes
- Thermo Fisher Scientific Inc. It is an American supplier of scientific instruments, reagents and consumables, and software services. Thermo Scientific's equipment, instruments, software, services and consumables meet needs from sampling, material characterization and chemical analysis to clinical diagnostics and production of biological-based therapeutics.
- CRISPR Therapeutics AG is a leading gene editing company focused on developing transformative gene-based medicines for critical diseases using its proprietary CRISPR/Cas9 platform.
- Intellia Therapeutics, Engineering Company Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental treatments to the clinic.
- Editas Medicine, Inc. commitment is to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines for people with critical illnesses around the world. Its mission is to discover, develop, manufacture and commercialize transformative, sustainable genomic medicines, many diseases.
- Sangamo Therapeutics, Inc. uses its deep scientific expertise and proprietary zinc finger technology to develop genomic therapies for patients with serious diseases.
- Bluebird Bio, Inc. Provides biotechnology products and services. The company offers gene therapy for serious genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. Bluebird Bio operates in the United States. Bluebird bio, inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic and orphan diseases.
- Cellectis S.A. is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells.
- Merck Group, Merck's employees develop, manufacture and market innovative products such as high-quality medicines, specialty chemicals for the biotech and pharmaceutical industries and academic research, as well as high-tech applications..
- Vigene Biosciences focuses on viral vector production and development, specializing in viral vector-based gene delivery for life science research, gene therapy and cell therapy purposes. Vigene offers AAV, lentivirus, and adenoviral-based products and custom services such as research-grade and cGMP grade AAV, lentiviral, and adenoviral vectors.
- Transposagen Biopharmaceuticals provides animal models of human disease for drug discovery and development. Transposagen Biopharmaceuticals, Inc. (“Transposagen”) is a leader in gene editing and integration technologies and services with applications in research and drug discovery and the bioproduction of therapeutic proteins and cells.
Global Genome Engineering Market By Company Profile
- Thermo Fisher Scientific Inc.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- CRISPR Therapeutics AG
- Intellia Therapeutics, Inc.
- Editas Medicine, Inc.
- Sangamo Therapeutics, Inc.
- Bluebird Bio, Inc.
- Cellectis S.A.
- Merck Group
- Vigene Biosciences
- Transposagen Biopharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section
Global Genome Engineering Market By Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Technologys
- Key Thickness Insights
- Secondary Data
- Major Secondary Technologys
- Secondary Technologys
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for medical carts Strategies
- Key Questions this Study will Answer
- Market Snippet, By Technology
- Market Snippet, By Application
- Market Snippet, By End User
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Technology
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
- Y-o-Y Growth Analysis (%), 2022 – 2032
- Segment Trends
- CRISPR
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- TALEN
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- ZFN
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Overview
- Market Segmentation, By Application, 2022 – 2032, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
- Y-o-Y Growth Analysis (%), 2022 – 2032
- Segment Trends
- Cell line Engineering
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Genetic Engineering
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Overview
- Market Segmentation, By End User, 2022 – 2032, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
- Y-o-Y Growth Analysis (%), 2022 – 2032
- Segment Trends
- Pharmaceutical and Biotechnology Companies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Academic and Research Institutes and Contract Research Organizations.
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
- Overview
- Global Market, By Region, 2022 – 2032, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
- Y-o-Y Growth Analysis (%), 2022 – 2032
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Technology, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
- Market Size and Forecast (US$ Bn), By End User, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Technology, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
- Market Size and Forecast (US$ Bn), By End User, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Technology, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
- Market Size and Forecast (US$ Bn), By End User, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Technology, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
- Market Size and Forecast (US$ Bn), By End User, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Technology, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
- Market Size and Forecast (US$ Bn), By End User, 2022 – 2032
- Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Thermo Fisher Scientific Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- CRISPR Therapeutics AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Intellia Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Editas Medicine, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Sangamo Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bluebird Bio, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Cellectis S.A.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck Group
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Vigene Biosciences
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Transposagen Biopharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The Genome Engineering Market is segmented into basis of on technical, application, end user and region.
Increasing funding and investment in research and development of new genetic engineering technologies, increasing demand for synthetic genes is expected to drive market growth, and the need to act against common cancers and infectious diseases is another primary driver for Global growth.
The global genome engineering market in North America accounted for highest revenue share as compared to other region. This can be attributed to increasing adoption of advanced techniques in the countries of the region.
The Key players operating in the Global Genome Engineering Market includes Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., Merck Group, Vigene Biosciences and Transposagen Biopharmaceuticals.